Company intelligence / Profile preview

Pear Tree Pharmaceuticals

Cambridge, Massachusetts, United States

Ownership: Public · PEAR
Employees: ~4
Development stage: Other

Overview

Pear Tree Pharmaceuticals developed at least one small molecule drug, PT-200, targeting estrogen receptors for the treatment of vaginitis; the program has been discontinued and the company was acquired by Dare Bioscience.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Financials

Market cap: $4.1M
Total revenue: $2.6M
Enterprise value: $-17.6M

Beyond the preview

Go deeper on Pear Tree Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pear Tree Pharmaceuticals.

Explore the full profile